

Ref No. NLL/CS/2013- 343

Dated: 13.08.2013

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Unaudited Financial Results for the period ended on 30th June 2013, as approved by the Board of Directors in their meeting held on even date i.e. 13th August, 2013.

Kindly take the same on record and oblige.

Thanking you,

Yours truly,

For Nectar Lifesciences Limited


Sunder Lal
Company Secretary

Encl. as above

CC:- Societe de la Bourse de Luxembourg S.A.
BP 165, L-2011 Luxembourg,
Telephone : (00352) 47 79 38-1
Fax: (00352) 47 32 98



NECTAR LIFESCIENCES LIMITED

Regd. Office: VIII, Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

Part I - Statement of Unaudited Financial Results for the Quarter ended 30.06.2013 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended 30.06.2013	Quarter ended 31.03.2013	Quarter ended 30.06.2012	Year ended 31.03.2013
		Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations				
	(a) Gross Sales	36150.94	38233.34	40413.21	167324.71
	Less : Excise Duty	1669.68	1469.48	1058.21	4843.28
	Net Sales	34481.26	36763.86	39355.00	162481.43
	(b) Other Operating Income	6.53	10.20	61.85	143.67
	Total Income from Operations (net)	34487.79	36774.06	39416.85	162625.10
2.	Expenses				
	(a) Cost of Materials consumed	24567.84	23323.59	24266.62	114652.24
	(b) Purchase of Stock in Trade	2736.95	663.98	3499.86	5999.80
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2948.51)	(1548.00)	1481.01	(6440.21)
	(d) Employee benefits expense	1398.70	1498.92	1075.06	4861.11
	(e) Depreciation and amortisation expense	2139.51	1961.03	1792.60	7595.61
	(f) Other expenses	2924.94	4159.99	3056.30	14544.15
	Total Expenses	30819.43	30059.51	35171.45	141212.70
3.	Profit from Operations before Other Income, finance costs and exceptional Items (1-2)	3668.36	6714.55	4245.40	21412.40
4.	Other Income	398.86	366.61	411.99	1604.03
5.	Profit before finance costs and exceptional Items (3+4)	4067.22	7081.16	4657.39	23016.43
6.	Finance costs	2576.78	3470.84	2492.77	11548.93
7.	Profit after finance costs but before exceptional Items (5-6)	1490.44	3610.32	2164.62	11467.50
8.	Exceptional Items	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	1490.44	3610.32	2164.62	11467.50
10.	Tax Expense	382.82	1046.11	561.85	2900.95
11.	Net Profit from ordinary activities after tax (9-10)	1107.62	2564.21	1602.77	8566.55
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1107.62	2564.21	1602.77	8566.55
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	84517.96
16.i	Earnings per Share (EPS) (before extraordinary items)				
	a) Basic	0.49	1.14	0.71	3.82
	b) Diluted	0.49	1.14	0.71	3.82
16.ii	Earnings per Share (EPS) (after extraordinary items)				
	a) Basic	0.49	1.14	0.71	3.82
	b) Diluted	0.49	1.14	0.71	3.82

Part II Select Information for the Quarter ended 30.06.2013

A	Particulars of shareholding				
1.	Public Shareholding				
	- Number of Shares	12,47,92,970	12,47,92,970	12,47,92,970	12,47,92,970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	9,94,68,000	9,94,68,000	9,94,68,000	9,94,68,000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.35	44.35	44.35
B	Investor Complaints	3 Months ended 30.06.2013			
	Pending at the beginning of Quarter				-
	Received During the Quarter				6
	Disposed Off During the Quarter				6
	Pending at the end of Quarter				-

Notes:

- The above financial results were reviewed by Audit Committee on 12.08.2013 and approved by the Board in its meeting held on 13.08.2013 and further limited reviewed by the Statutory Auditors of the Company.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- As per Accounting Standard 11, accounting of the effect of changes in foreign exchange rates will be ascertained at the end of the year and hence the same is not considered in these quarterly results.
- The above financial results are on stand alone basis.
- The company is exclusively in the pharmaceutical business segment.

Certified to be true copy

For Nectar Lifesciences Limited

Sunder Lal

Company Secretary

By Order of the Board of Directors
of Nectar Lifesciences Limited
sd/-

(Sanjiv Goyal)

Dated: 13.08.2013

Place: Chandigarh

Chairman & Managing Director